Do you have nail psoriasis?
If you have mild to moderate nail psoriasis (nPS) and you live in Australia, then you may be eligible to participate in a new clinical trial looking at the safety, tolerability and efficacy of a potential new topical medication. The trial is 32 weeks long with a 2 week follow up. It is being conducted at multiple clinical sites across Australia. For the first 16 weeks patients will treat one hand and one target skin plaque with active medication and one hand and target skin plaque with placebo. Afterwards, all patients will receive active medication to treat both hands and target skin plaques and will have the option to treat all plaque psoriasis they may have.
Please enter your details and we will connect you if you meet the eligibility criteria.
Disclaimer - Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. AT193 has not been demonstrated to be safe or effective for any indication and is not available for sale in Australia or any other country.
Your personal information is being requested to allow an initial assessment to be made about your potential eligibility for participation in a clinical trial. By submitting the requested information, you are consenting for your personal and health information to be viewed by representatives from Azora Therapeutics and its affiliates, and disclosed to a relevant trial site for further assessment. Your data will be stored on our servers until the completion of the study. It will not be used for any purposes other than the purpose stated above.